Rebecca Auzins is a Masters by Research candidate and Research Assistant in the cancer program.
Predictive biomarkers of response with accurate sensitivity are currently in high demand. While there are treatment options available for patients with late-stage melanoma, they do not always successfully produce a response. With ctDNA at the forefront of current biomarker research, its use is limited to patients which present with known tumour-specific mutations, unlike autoantibodies, which have shown promising results as cancer biomarkers, however, their efficacy as predictors of response has not been thoroughly researched. This project will aim to identify an autoantibody that is indicative of response for late-stage melanoma patients undergoing immunotherapy treatments.